albuterol and Constriction, Pathological studies

Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Research Excerpts

Excerpt	Relevance	Reference
"The protective efficacy of oral cetirizine, a selective and potent H1-receptor antagonist, against the immediate bronchoconstrictive response to allergen inhalation and exercise challenge was evaluated in 16 subjects with stable, predominantly mild asthma."	9.06	Effects of oral cetirizine, a selective H1 antagonist, on allergen- and exercise-induced bronchoconstriction in subjects with asthma. ( Dauphinee, B; Djahed, B; Gong, H; Tashkin, DP; Wu, TC, 1990)
"The protective efficacy of oral cetirizine, a selective and potent H1-receptor antagonist, against the immediate bronchoconstrictive response to allergen inhalation and exercise challenge was evaluated in 16 subjects with stable, predominantly mild asthma."	5.06	Effects of oral cetirizine, a selective H1 antagonist, on allergen- and exercise-induced bronchoconstriction in subjects with asthma. ( Dauphinee, B; Djahed, B; Gong, H; Tashkin, DP; Wu, TC, 1990)
"To determine the effect of pharmacologic modulation of alterations of peripheral blood T-cell subsets caused by antigen-induced bronchoconstriction, we administered albuterol immediately after antigen-induced bronchoconstriction in a double-blind to protocol to 12 atopic asthmatic subjects."	5.06	Antigen-induced T-cell changes: modulation by pharmacologic agents. ( Gerblich, A; Salik, H; Schuyler, M; Varghese, J, 1990)
"We performed pulmonary function tests and HRCT on eight asthmatic adults and two nonasthmatic control adults under three conditions: baseline, after methacholine inhalation, and after albuterol inhalation."	3.69	High-resolution computed tomography of airway changes after induced bronchoconstriction and bronchodilation in asthmatic volunteers. ( Chen, DR; Fahy, JV; Gamsu, G; Kee, ST, 1996)
" Dosing was followed by exercise challenges at 2, 8."	2.73	Single-dose montelukast or salmeterol as protection against exercise-induced bronchoconstriction. ( Langdon, RB; Legrand, C; Loeys, T; Pearlman, DS; Philip, G; Reiss, TF; Villarán, C, 2007)
"Montelukast was effective in treating EIB without inducing tolerance and provided superior (P	2.69	Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. ( Chuchalin, AG; Gunawardena, KA; Helbling, A; Jasan, J; Langley, SJ; Laurenzi, M; Lee, TH; Leff, JA; Menten, J; O'Neill, SJ; Suskovic, S; van Noord, JA; Villaran, C, 1999)

Research

Studies (15)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Area Under the Curve for FEV1 Percent Change From Preexercise Baseline During the 60 Minutes Following Exercise Challenge (AUC 0-60 Min) at 2 Hours Postdose

Timeframe	Studies, this research(%)	All Research%
pre-1990	6 (40.00)	18.7374
1990's	4 (26.67)	18.2507
2000's	5 (33.33)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Fukkuda, T	1
Barbato, E	1
Piscione, F	1
Bartunek, J	1
Galasso, G	1
Cirillo, P	1
De Luca, G	1
Iaccarino, G	1
De Bruyne, B	1
Chiariello, M	1
Wijns, W	1
Suda, T	1
Hashizume, H	1
Aoshima, Y	1
Yokomura, K	1
Sato, J	1
Inui, N	1
Nakamura, Y	1
Fujisawa, T	1
Enomoto, N	1
Chida, K	1
Philip, G	1
Pearlman, DS	1
Villarán, C	2
Legrand, C	1
Loeys, T	1
Langdon, RB	1
Reiss, TF	1
Broski, SE	1
Amundson, DE	1
Richards, IM	1
Eady, RP	1
Jackson, DM	1
Orr, TS	1
Pritchard, DI	1
Vendy, K	1
Wells, E	1
Orehek, J	2
Charpin, D	1
Velardocchio, JM	1
Grimaud, C	2
Kee, ST	1
Fahy, JV	1
Chen, DR	1
Gamsu, G	1
O'Neill, SJ	1
Helbling, A	1
van Noord, JA	1
Lee, TH	1
Chuchalin, AG	1
Langley, SJ	1
Gunawardena, KA	1
Suskovic, S	1
Laurenzi, M	1
Jasan, J	1
Menten, J	1
Leff, JA	1
Casterline, CL	1
Evans, R	1
Ward, GW	1
Gayrard, P	1
Charpin, J	1
Gong, H	1
Tashkin, DP	1
Dauphinee, B	1
Djahed, B	1
Wu, TC	1
Varghese, J	1
Gerblich, A	1
Salik, H	1
Schuyler, M	1
Menendez, R	1
Lowe, RS	1
Kersey, J	1
Lim, TK	1
Ang, SM	1
Rossing, TH	1
Ingenito, EP	1
Ingram, RH	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Double-Blind, Randomized Multicenter, 3-Period, Crossover Study to Evaluate the Effects of a Single Dose of Montelukast Compared With Placebo and Salmeterol on Exercise-Induced Bronchoconstriction[NCT00245570]	Phase 3	47 participants (Actual)	Interventional	2005-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"The measure included only the area below the pre-exercise~baseline" (NCT00245570)
Timeframe: 0-60 minutes after the exercise challenge at 2 hours postdose

Area Under the Curve for FEV1 Percent Change From Preexercise Baseline During the 60 Minutes Following Exercise Challenge (AUC 0-60 Min) at 24 Hours Postdose

Intervention	Percent * minutes (Mean)
Montelukast 10 mg	254.60
Salmeterol 50-μg	293.05
Placebo	710.43

The measure included only the area below the pre-exercise baseline (NCT00245570)
Timeframe: 0-60 minutes after the exercise challenge at 24 hours postdose

Area Under the Curve for FEV1 Percent Change From Preexercise Baseline During the 60 Minutes Following Exercise Challenge (AUC 0-60 Min) at 8.5 Hours Postdose

Intervention	Percent * minutes (Mean)
Montelukast 10 mg	231.09
Salmeterol 50-μg	554.93
Placebo	395.96

The measure included only the area below the pre-exercise baseline (NCT00245570)
Timeframe: 0-60 minutes after the exercise challenge at 8.5 hours postdose

Maximum Percent Fall in FEV1 After Exercise Challenge at 24 Hours Post-dose in Patients With EIB

Intervention	Percent * minutes (Mean)
Montelukast 10 mg	191.01
Salmeterol 50-μg	276.26
Placebo	511.28

In patients with EIB, the percent change from pre-exercise baseline FEV, to the lowest FEV1 within 60 minutes after exercise challenge (24 hours post-dose). The FEV1 measurement obtained 5 minutes before the exercise challenge was the baseline, and was specific to each exercise challenge. (NCT00245570)
Timeframe: 0-60 minutes after the exercise challenge performed 24 hours after a single oral dose

Maximum Percent Fall in FEV1 After Exercise Challenge at 8.5 Hours Post-dose in Patients With EIB

Intervention	Percent Change from Baseline (Mean)
Montelukast 10 mg	10.09
Salmeterol 50-μg	16.22
Placebo	13.64

In patients with EIB, the percent change from pre-exercise baseline FEV, to the lowest FEV1 within 60 minutes after exercise challenge (8.5 hours post-dose). The FEV1 measurement obtained 5 minutes before the exercise challenge was the baseline, and was specific to each exercise challenge. (NCT00245570)
Timeframe: 0-60 minutes after the exercise challenge performed 8.5 hours after a single oral dose

Maximum Percent Fall in Forced Expiratory Volume in 1 Second (FEV1) After Exercise Challenge at 2 Hours Post-dose in Patients With Exercise-Induced Bronchoconstriction (EIB)

Intervention	Percent Change from Baseline (Mean)
Montelukast 10 mg	11.60
Salmeterol 50-μg	11.01
Placebo	16.65

In patients with EIB, the percent change from pre-exercise baseline FEV1 to the lowest FEV1 within 60 minutes after exercise challenge (2 hours post-dose). The FEV1 measurement obtained 5 minutes before the exercise challenge was the baseline, and was specific to each exercise challenge. (NCT00245570)
Timeframe: 0-60 minutes after the exercise challenge performed 2 hours after a single oral dose

Time to Recovery From Maximum Percentage Decrease in FEV1 After Exercise Challenge at 2 Hours Postdose

Intervention	Percent Change from Baseline (Mean)
Montelukast 10 mg	13.15
Salmeterol 50-μg	10.46
Placebo	21.86

The time to recovery from maximum percent fall is the duration between the time at which the maximum percent fall in FEV1 after exercise challenge occurs and the time when FEV1 returns to within 5% of the preexercise baseline for the first time. (NCT00245570)
Timeframe: Exercise challenge at 2 hours postdose

Time to Recovery From Maximum Percentage Decrease in FEV1 After Exercise Challenge at 24 Hours Postdose

Intervention	Minutes (Mean)
Montelukast 10 mg	16.63
Salmeterol 50-μg	17.58
Placebo	42.70

"The time to recovery from maximum percent fall is the~duration between the time at which the maximum percent fall in FEV1 after exercise challenge occurs and the~time when FEV1 returns to within 5% of the preexercise baseline for the first time." (NCT00245570)
Timeframe: Exercise challenge at 24 hours postdose

Time to Recovery From Maximum Percentage Decrease in FEV1 After Exercise Challenge at 8.5 Hours Postdose

Intervention	Minutes (Mean)
Montelukast 10 mg	11.04
Salmeterol 50-μg	29.75
Placebo	23.31

Number of Patients Requiring β-Agonist Rescue Medication After Exercise Challenge at 2 Hours Postdose

Intervention	Minutes (Mean)
Montelukast 10 mg	10.70
Salmeterol 50-μg	13.82
Placebo	32.34

(NCT00245570)
Timeframe: 0-90 minutes after the exercise challenge performed at 2 hours postdose

Number of Patients Requiring β-Agonist Rescue Medication After Exercise Challenge at 24 Hours Postdose

Intervention	Participants (Number)
	Patients Requiring Rescue Medication	Patients Not Requiring Rescue Medication
Montelukast 10 mg	3	44
Placebo	9	38
Salmeterol 50-μg	4	42

(NCT00245570)
Timeframe: 0-90 minutes after the exercise challenge performed at 24 hours postdose

Number of Patients Requiring β-Agonist Rescue Medication After Exercise Challenge at 8.5 Hours Postdose

Intervention	Participants (Number)
	Patients Requiring Rescue Medication	Patients Not Requiring Rescue Medication
Montelukast 10 mg	3	43
Placebo	6	40
Salmeterol 50-μg	6	40

(NCT00245570)
Timeframe: 0-90 minutes after the exercise challenge performed at 8.5 hours postdose

Article	Year
Single-dose montelukast or salmeterol as protection against exercise-induced bronchoconstriction. Chest, 2007, Volume: 132, Issue:3 Topics: Acetates; Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Bronchial Diseases; Bronchodilator Ag	2007
Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. The Journal of allergy and clinical immunology, 1999, Volume: 104, Issue:3 Pt 1 Topics: Acetates; Adolescent; Adult; Albuterol; Asthma, Exercise-Induced; Bronchial Diseases; Bronchodilator	1999
Effects of oral cetirizine, a selective H1 antagonist, on allergen- and exercise-induced bronchoconstriction in subjects with asthma. The Journal of allergy and clinical immunology, 1990, Volume: 85, Issue:3 Topics: Administration, Oral; Adult; Albuterol; Allergens; Asthma; Asthma, Exercise-Induced; Bronchi; Bronch	1990
Antigen-induced T-cell changes: modulation by pharmacologic agents. Lung, 1990, Volume: 168, Issue:2 Topics: Administration, Inhalation; Albuterol; Antigens; Asthma; Bronchi; Bronchial Provocation Tests; Const	1990

Article	Year
Role of beta2 adrenergic receptors in human atherosclerotic coronary arteries. Circulation, 2005, Jan-25, Volume: 111, Issue:3 Topics: Acetylcholine; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-2 Receptor Antagonists; Albutero	2005
Management of interleukin-2-induced severe bronchoconstriction. The European respiratory journal, 2007, Volume: 29, Issue:3 Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aged; Aged, 80 and over; Albuterol; Androstadi	2007
Paradoxical response to levalbuterol. The Journal of the American Osteopathic Association, 2008, Volume: 108, Issue:4 Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Diseases; Constriction, Pathologic; Hu	2008
Ascaris-induced bronchoconstriction in primates experimentally infected with Ascaris suum ova. Clinical and experimental immunology, 1983, Volume: 54, Issue:2 Topics: Airway Resistance; Albuterol; Allergens; Animals; Ascariasis; Ascaris; Asthma; Atropine; Benzopyrans	1983
Bronchomotor effect of bronchoconstriction-induced deep inspirations in asthmatics. The American review of respiratory disease, 1980, Volume: 121, Issue:2 Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Carbachol; Constr	1980
High-resolution computed tomography of airway changes after induced bronchoconstriction and bronchodilation in asthmatic volunteers. Academic radiology, 1996, Volume: 3, Issue:5 Topics: Adult; Albuterol; Asthma; Bronchi; Bronchial Diseases; Bronchoconstrictor Agents; Bronchodilator Age	1996
The effect of atropine and albuterol aerosols on the human bronchial response to histamine. The Journal of allergy and clinical immunology, 1976, Volume: 58, Issue:5 Topics: Administration, Intranasal; Aerosols; Albuterol; Atropine; Bronchi; Constriction, Pathologic; Forced	1976
Mechanisms of the bronchoconstrictor effects of deep inspiration in asthmatic patients. Thorax, 1979, Volume: 34, Issue:2 Topics: Adolescent; Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Constriction, Pathologic; Cromolyn	1979
Benzalkonium chloride and bronchoconstriction. The Journal of allergy and clinical immunology, 1989, Volume: 84, Issue:2 Topics: Albuterol; Asthma; Benzalkonium Compounds; Bronchi; Constriction, Pathologic; Drug Therapy, Combinat	1989
The effects of deep inhalation on maximal expiratory flow during intensive treatment of spontaneous asthmatic episodes. The American review of respiratory disease, 1989, Volume: 140, Issue:2 Topics: Adult; Albuterol; Asthma; Constriction, Pathologic; Dilatation, Pathologic; Female; Glucocorticoids;	1989

albuterol and Constriction, Pathological